Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii

Biochemical Pharmacology

Volumn 51, Issue 12, 1996, Pages 1687-1700

  El Kouni, Mahmoud H ^a   Naguib, Fardos N M ^a   Panzica, Raymond P ^b   Otter, Brian A ^c   Chu, Shih Hsi ^d   Gosselin, Gilles ^e   Chu, Chung K ^f   Schinazi, Raymond F ^g,h   Fulmer Shealy, Y ⁱ   Goudgaon, Naganna ^j   Ozerov, Alexander A ^k   Ueda, Tohru ^l   Iltzsch, Max H ^m  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIV MONTPELLIER   (France)

^f UNIVERSITY OF GEORGIA   (United States)

^g ATLANTA VA MEDICAL CENTER   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SOUTHERN RESEARCH INSTITUTE   (United States)

^j FLORIDA A AND M UNIVERSITY   (United States)

^k VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^l HOKKAIDO UNIVERSITY   (Japan)

^m UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

ligands; phosphorylase; structure activity; toxoplasma; uridine

Indexed keywords

2' DEOXYRIBOSIDE; 2',3' DIDEOXYNUCLEOSIDE; 2',5' DIDEOXYNUCLEOSIDE; 2,2' ANHYDROURIDINE; 2,5' ANHYDROURUDINE; 3 DEAZAURIDINE; 3' DEOXYRIBOSIDE; 4 THIOURIDINE; 5 (BENZYLOXYBENZYL) 2,2' ANHYDROURIDINE; 5 BENZYLURIDINE; 5 BROMOURIDINE; 5 METHYLURIDINE; 5' DEOXYRIBOSIDE; ACYCLOURIDINE; ARABINOSYL URACIL; AZAURIDINE; CYTIDINE; DEOXYRIBOSIDE; FLUOROURIDINE; IODOURIDINE; NUCLEOSIDE DERIVATIVE; PENTOSE; RIBOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL; URIDINE; URIDINE DERIVATIVE; URIDINE PHOSPHORYLASE; XYLOSIDE;

ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; ENANTIOMER; ENZYME BINDING; HOST; ISOMER; NONHUMAN; PARASITE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TOXOPLASMA GONDII;

EID: 0029936206     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00213-4     Document Type: Article

References (75)

1. Luft BJ and Remington JS, Toxoplasmic encephalitis. J Infect Dis 157: 1-6, 1988.
2. Luft BJ, Toxoplasma gondii. In: Parasitic Infections in the Compromised Host (Eds. Walzer PD and Genta RM), pp. 179-279. Marcel Dekker, New York, 1989.
3. McCabe R and Remington JS, Toxoplasmosis: The time has come. N Engl J Med 318: 313-315, 1988.
4. Mills J, Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS. Rev Infect Dis 8: 1001-1011, 1986.
5. Asai T, O'Sullivan WJ, Kobayashi M, Gero AM, Yokogawa M and Tatibana M, Enzymes of de novo pyrimidine biosynthetic pathways in Toxoplasma gondii. Mol Biochem Parasitol 7: 89-100, 1983.
6. Iltzsch MH, Pyrimidine salvage pathways in Toxoplasma gondii. J Eukaryot Microbiol 40: 24-28, 1993.
7. Iltzsch MH and Klenk EE, Structure-activity relationship of nucleobase ligands of uridine phosphorylase from Toxoplasma gondii. Biochem. Pharmacol 46: 1849-1858, 1993.
8. Abrams H, Ho L and Chu SH, Synthesis of pyrimidine acyclonucleosides. J Heterocycl Chem 18: 947-950, 1981.
9. Niedzwicki JG, Chu SH, el Kouni MH, Rowe EC and Cha S, 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem Pharmacol 31: 1857-1861, 1982.
10. Chu SH, Chen ZH, Rowe EC, Naguib FNM, el Kouni MH and Chu YM, Synthesis and biological activity of hydroxymethyl analogs of 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine. Nucleosides Nucleotides 3: 303-311, 1984.
11. Chu SH, Weng ZY, Chen ZH, Rowe EC, Chu E, Naguib FNM, el Kouni MN, Cha S and Chu MY, Synthesis of 5-benzyl and 5-benzyloxybenzyl 2,2′-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase. Nucleosides Nucleotides 7: 91-102, 1988.
12. Chu S-H, Chen ZH, Weng ZY, Rowe EC, Chu EC and Chu M-Y, Synthesis of aminomethyl and amino analogs of 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine. J Heterocycl Chem 24: 989-995, 1987.
13. Chu S-H, Chen ZH, Weng ZY, Rowe EC, Chu E and Chu M-Y, Synthesis of variants of 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine. J Hetercycl Chem 23: 1651-1655, 1986.
14. Schinazi RF, Arbiser J, Lee J-JS, Kalman TI and Prusoff WH, Synthesis and biological activity of 5-selenenyl-substituted pyrimidine nucleosides. J Med Chem 29: 1293-1295, 1986.
15. Goudgaon NM, McMillan A and Schinazi RF, 1-(Ethoxymethyl)-6-(phenylselenenyl)-pyrimidine nucleosides against human immunodeficiency virus types 1 and 2. Antiviral Chem Chemother 3: 263-266, 1992.
16. Goudgaon NM and Schinazi RF, Activity of acyclic 6-(phenylselenenyl) pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. J Med Chem 34: 3305-3309, 1991.
17. Goudgaon NM, Naguib FNM, el Kouni MH and Schinazi RF, Phenylselenenyl- and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase. J Med Chem 36: 4250-4254, 1993.
18. Goudgaon NM, Lee HJ and el Kouni MH, 5-Arylthioacyclouridine: Potent inhibitors of uridine phosphorylase. Proc Am Assoc Cancer Res 36: 1716, 1995.
19. Naguib FNM, Levesque DL, Wang E-C, Panzica RP and el Kouni MH, 5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem Pharmacol 46: 1273-1283, 1993.
20. Levesque DL, Wang E-C, Wei DC, Tzeng C-C, Panzica RP, Naguib FNM and el Kouni MH, Synthesis of a new class of uridine phosphorylase inhibitors. J Heterocycl Chem 40: 1399-1404, 1993.
21. Chu CK, Acyclo C-nucleosides. Synthesis of acyclopseudocytidine and its derivatives. J Heterocycl Chem 21: 9-11, 1984.
22. Purkayastha S and Panzica RP, Synthesis of certain 6-,alkylthio-2,2′-anhydro-5-azauridines. J Heterocycl Chem 27: 753-757, 1990.
23. Ozerov AA, Novikov MS, Brel AK, Andeeva OT, Vladyko GV, Boreko BI, Korobchenko LV and Vervetchenko SG, Synthesis and antiviral activity of new unsaturated pyrimidine acyclonucleosides. Khim-Farm Zh 25: 44-47, 1991.
24. Kawana M, Nishikawa M, Yamasaki N and Kuzuhara H, Facile transformation of β-D-ribofuranosyl purines and pyrimidines into their respective 3′-deoxy-threo-pentofuranosyl nucleosides. J Chem Soc Perkin Trans I: 1593-1596, 1989.
25. Lin T-S, Yang J-H, Liu M-C, Shen Z-Y, Cheng Y-C, Prusoff WH, Birnbaum GI, Giziewicz J, Ghazzouli I, Brankovan V, Feng J-S and Hsiung G-D, Synthesis and anticancer activity of various 3′-deoxy pyrimidine nucleoside analogues and crystal structure of 1-(3-deoxy-β-D-threo-pentofuranosyl)cytosine. J Med Chem 34: 693-701, 1991.
26. Kawana M and Kuzuhara H, General method for the synthesis of 2′-azido-2′,3′-dideoxynucleosides by the use of [1,2]hydride shift and β-elimination reactions. J Chem Soc Perkin Trans I: 469-478, 1992.
27. Debart F, Rayner B, Degols G and Imbach J-L, Synthesis and base pairing properties of nuclease-resistant α-anomeric dodecaribonucleotide α-[r(UCUUAACCCACA)]. Nucleic Acids Res 20: 1193-1200, 1992.
28. 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide α-[d(CpCpTpTpCpC)] with its complement β-[d(GpGpApApGpG)]. Nucleic Acids Res 14: 5019-5035, 1986.
29. Gosselin G, Bergogne MC, de Rudder J, De Clercq E and Imbach J-L, Systematic synthesis and biological evaluation of α- and β-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues. J Med Chem 29: 203-213, 1986.
30. Holý A, L-Uridine. In: Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods, and Techniques. Part III (Eds. Townsend LB and Tipson RS), pp. 109-111. John Wiley, New York, 1986.
31. Holý A, Nucleic acid components and their analogues. CLIII. Preparation of 2′-deoxy-L-ribonucleosides of the pyrimidine series. Collect Czech Chem Commun 37: 4072-4087, 1972.
32. Lin TS, Lou MZ, Liu MC, Pai SB, Dutschman GE and Cheng Y-S, Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J Med Chem 37: 798-803, 1994.
33. Gosselin G, Bergogne MC and Imbach J-L, Obtention d'arabinofurannonucléosides par transformation chimique de certains xylofurannonucléosides. Nucleosides Nucleotides 3: 265-275, 1984.
34. Gosselin G, Bergogne M-C, De Rudder J, De Clercq E and Imbach J-L, Systematic synthesis and biological evaluation of α- and β-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases. J Med Chem 30: 982-991, 1987.
35. Gosselin G, Bergogne MC and Imbach J-L, Synthesis and antiviral evaluation of β-L-xylofuranosyl nucleosides of the five naturally occurring nucleic acid bases. J Heterocycl Chem 30: 1229-1233, 1993.
36. Abdel-Megied AE-S, Pedersen EB and Nielsen CM, Synthesis of 2′-azido,2,2′-anhydro and 2,5′-anhydro nucleosides with potential anti-HIV activity. Synthesis 313-317, 1991.
37. Shealy YF and O'Dell CA, Synthesis of carbocyclic analogs of uracil nucleosides. J Heterocycl Chem 13: 1015-1020, 1976.
38. Shealy YF, O'Dell CA and Thorpe MC, Synthesis of carbocyclic analogues of thymine nucleosides and related 1-substituted thymines. J Heterocycl Chem 18: 383-389, 1981.
39. Shealy YF, O'Dell CA, Arnett G and Shannon WM, Synthesis and antiviral activity of carbocyclic analogues of 5-ethyl-2′-deoxyuridine and of 5-ethynyl-deoxyuridine. J Med Chem 29: 79-84, 1986.
40. el Kouni MH, Naguib FNM, Chu S-H, Cha S, Ueda T, Gosselin G, Imbach J-L, Shealy YF and Otter BA, Effect of the N-glycosidic bond conformation and modifications in the pentose moiety on the binding of nucleoside ligands to uridine phosphorylase. Mol Pharmacol 34: 104-110, 1988.
41. Shealy YF, O'Dell CA, Shannon WM and Arnett G, Carbocyclic analogues of 5′-amino-5′-deoxy- and 3′-amino-3′-deoxythymidine. J Med Chem 29: 483-488, 1986.
42. O'Dell CA and Shealy YF, Carbocyclic analogues of 3′,4′-didehydro-2-deoxyribofuranosyl-2,4(1H,3H)-pyrimidinediones. Nucleosides Nucleotides 13: 1929-1937, 1994.
43. Chu CK, Schinazi RF, Arnold BH, Canon DL, Doboszewski B, Bhadti VB and Gu Z, Comparative activity of 2′,3′-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem Pharmacol 37: 3543-3548, 1988.
44. Choi W-B, Wilson LJ, Yeola S, Liotta DC and Schinazi RF, In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogues. J Am Chem Soc 113: 9377-9379, 1991.
45. Sano T and Ueda T, A facile synthesis of 6,3′-methano-uridine and -cytidine from a 3-ketosugar (Nucleosides and nucleotides. LXVIII). Chem Pharm Bull (Tokyo) 34: 423-425, 1986.
46. Ueda T, Usui H, Shuto S and Inoue H, Synthesis of 6,5′-cyclo-5′-deoxyuridines by radical cyclization (Nucleosides and nucleotides. L). Chem Pharm Bull (Tokyo) 32: 3410-3416, 1984.
47. Suzuki Y, Matsuda A and Ueda T, Synthesis of 6,5′-cyclo-2′,5′-dideoxypyrimidine nucleosides (Nucleosides and nucleotides. LXXII). Chem Pharm Bull (Tokyo) 35: 1085-1092, 1987.
48. Kim HO, Shanmuganathan K, Alves AJ, Jeong LS, Beach JW, Schinazi RF, Chang C-N, Cheng Y-C and Chu CK, Potent anti-HIV and anti-HBV activities of (-)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses. Tetrahedron Lett 33: 6899-6902, 1992.
49. Yang T-F, Kotra LP, Teng Q, Naguib FNM, Sommadossi J-P, el Kouni MH and Chu CK, Synthesis of [4-(hydroxy)tetrahydrofuran-2-yl]-nucleosides as a novel class of uridine phosphorylase inhibitors. Tetrahedron Lett 36: 983-986, 1995.
50. Sarma MSP, Megati S, Klein RS and Otter BA, A convenient synthesis of D-psicofuranyosyl nucleosides. Nucleosides Nucleotides 14: 393-396, 1995.
51. 5′6-methanourdine - A new type of pyrimidine cyclonucleoside. Nucleosides Nucleotides 11: 615-635, 1992.
52. Wilkinson GN, Statistical estimations in enzyme kinetics. Biochem J 80: 324-332, 1961.
53. Cleland WW, The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: Nomenclature and theory. Biochim Biophys Acta 67: 173-187, 1963.
54. Dixon M and Webb EC, Enzymes. Academic Press, New York, 1979.
55. Niedzwicki JG, el Kouni MH, Chu SH and Cha S, Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase. Biochem Pharmacol 30: 2097-2101, 1981.
56. Park KS, el Kouni MH, Krenitsky TA, Chu S-H and Cha S, Inhibition of uridine phosphorylase from Escherichia coli by benzylacyclouridines. Biochem Pharmacol 35: 3853-3855, 1986.
57. Naguib FNM, el Kouni MH, Chu SH and Cha S, New analogues of benzylacyclouridines, specific and potent inhibitors of uridine phosphorylase from human and mouse livers. Biochem Pharmacol 36: 2195-2201, 1987.
58. el Kouni MH, Naguib FNM, Niedzwicki JG, Iltzsch M and Cha S, Uridine phosphorylase from Schistosoma mansoni. J Biol Chem 263: 6081-6086, 1988.
59. Veres Z, Szabolcs A, Szinai I, Dénes G, Kajtár-Peredy M and Ötvös L, 5-Substituted-2,2′-anhydrouridines, potent inhibitors of uridine phosphorylase. Biochem Pharmacol 34: 1737-1740, 1985.
60. Drabikowska AK, Lissowska L, Veres Z and Shugar D, Inhibitor properties of some 5-substituted uracil acyclonucleosides and 2,2′-anhydrouridines versus uridine phosphorylase from E. coli and mammalian sources. Biochem Pharmacol 36: 4125-4128, 1987.
61. Drabikowska AK, Lissowska L, Dramiski M, Zgit-Wroblewska A and Shugar D, Acyclonucleoside analogues consisting of 5- and 6-substituted uracils and different acyclic chains: Inhibitory properties vs purified E. coli uridine phosphorylase. Z Naturforsch 42C: 288-296, 1987.
62. Veres Z, Neszmélyi A, Szabolcs A and Dénes G, Inhibition of uridine phosphorylase by pyrimidine nucleoside analogs and consideration of substrate binding to the enzyme based on solution conformation as seen by NMR spectroscopy. Eur J Biochem 178: 173-181, 1988.
63. Veres Z, Neszmélyi A, Szabolcs A, Kiss ÁI and Dénes G, The effect of the 3′-OH group on the conformation and binding ability of anhydropyrimidine nucleosides to uridine phosphorylase. Arch Biochem Biophys 286: 1-5, 1991.
64. el Kouni MH, el Kouni MM and Naguib FNM, Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: Implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 53: 3687-3693, 1993.
65. Cha S, Kinetics of enzyme reactions with competing alternative substrates. Mol Pharmacol 4: 621-629, 1968.
66. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
67. 1H NMR analyses of 5-(m-benzyloxybenzyl)-1-[(1,3-dihydroxy-2-propoxy)methyl]-uracil, an acyclonucleoside inhibitor of uridine phosphorylase. Can J Chem 64: 2376-2381, 1986.
68. Davis DB, Conformation of nucleoside and nucleotides. Prog NMR Spectroscopy 12: 135-225, 1978.
69. Krajewska E and Shugar D, Pyrimidine ribonucleoside phosphorylase activity vs 5- and/or 6-substituted uracil and uridine analogues, including conformational aspects. Biochem Pharmacol 31: 1097-1102, 1982.
70. Bose R and Yamada EW, Uridine phosphorylase, molecular properties and mechanism of catalysis. Biochemistry 13: 2051-2056, 1974.
71. Niedzwicki JG, Chu SH, el Kouni MH and Cha S, Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases. Biochem Pharmocol 32: 399-415, 1983.
72. Yathindra Y and Sundaralingam M, Conformational analysis of arabinonucleosides and nucleotides. A comparison with the ribonucleosides and nucleotides. Biochim Biophys Acta 564: 301-310, 1979
73. Etzold G, Preussel B and Langen P, Structural requirements for the inhibition of uridine-deoxyuridine phosphorylase by thymine nucleosides containing an unnatural carbohydrate moiety. Mol Pharmacol 4: 20-24, 1968.
74. Van Roey P, Taylor EW, Chu CK and Schinazi RF, Conformational analysis of 2′,3′-didehydro-2′,3′-dideoxypyrimidine nucleosides. J Am Chem Soc 115: 5365-5371, 1993.
75. Baker BR and Kelly JL, Irreversible enzyme inhibitors. CLXXI. Inhibition of FUDR phosphorylase from Walker 256 rat tumor by 5-substituted uracils. J Med Chem 13: 461-467, 1970.